#541
|
|||
|
|||
Ó äî÷êè äèàãíîç : îðãàíè÷åñêîå ïîðàæåíèå ÖÍÑ, ïîñòãåìîððàãè÷åñêàÿ ãåìèàòðîôèÿ ãîëîâíîãî ìîçãà, êîðêîâî-ïîäêîðêîâàÿ àòðîôèÿ, ñïàñòè÷åñêèé òåòðàïàðåç.
Çíà÷èò, ÿ ïðàâèëüíî ïîíÿë, ÷òî òàê íàçûâàåìîå ëå÷åíèå ñòâîëîâûìè êëåòêàìè íåâîçìîæíî ïðè ýòîì äèàãíîçå, òàê ? |
#542
|
|||
|
|||
Ïðàâèëüíî.
|
#543
|
|||
|
|||
Áîþñü, ÷òî ýòî óòîïèÿ... çà äåíüãè ïàöèåíòà.
|
#544
|
|||
|
|||
[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]
âîçìîæíî, ÷òî ýòîé ññûëêå Âû íàéäåòå è ëó÷øåå ìåñòî íà ôîðóìå |
#545
|
|||
|
|||
Ïðàâèëüíî ëè ÿ ïîíèìàþ, ÷òî èãëîóêàëûâàíèå îòíîñèòñÿ ê íåòðàäèöèîííûì ìåòîäàì ëå÷åíèÿ ? Ó íàñ òàêàÿ ñèòóàöèÿ, äî÷êå 3,5 ãîäà, ó íå¸ äèàãíîç : îðãàíè÷åñêîå ïîðàæåíèå ÖÍÑ, ïîñòãåìîððàãè÷åñêàÿ ãåìèàòðîôèÿ ãîëîâíîãî ìîçãà, êîðêîâî-ïîäêîðêîâàÿ àòðîôèÿ, ñïàñòè÷åñêèé òåòðàïàðåç. Íàì ïðåäàãàþò êóïèòü 100 èãë è ñäåëàòü èãëîóêàëûâàíèå. ×òî ïîñîâåòóåòå ? Ýòî ìîæåò áûòü ýôôåêòèâíî â ëå÷åíèè ïàðåçà èëè ëó÷øå îòêàçàòüñÿ ?
|
#546
|
|||
|
|||
|
#547
|
|||
|
|||
Õî÷åòñÿ çàòðîíóòü åùå îäíó òåìó, íà êîòîðîé â ïîñëåäíåå âðåìÿ íàæèâàåòñÿ î÷åíü ìíîãî ëþäåé.
Ðå÷ü èäåò î ñïåêóëÿöèÿõ ñ "êîðàëëîâîé âîäîé" è ìèêðîãèäðèíîì â ÷àñòíîñòè. Åñòü íåáîëüøîå ðàíäîìèçèðîâàííîå èññëåäîâàíèå, êîòîðîå íè÷åì õîðîøèì ìèêðîãèäðèíó íå ñâåòèò [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] Effects of microhydrin supplementation on endurance performance and metabolism in well-trained cyclists. Glazier LR, Stellingwerff T, Spriet LL. Dept of Human Biology and Nutritional Sciences, University of Guelph, Guelph, Ontario, Canada N1G 2W1. This study investigated whether the supplement Microhydrin (MH) contains silica hydride bonds (Si-H) and if Microhydrin supplementation increased performance or altered metabolism compared to placebo (PL) during prolonged endurance cycling. Seven endurance-trained male cyclists consumed 9.6 g of MH or PL over 48 h in a randomized, double-blind, crossover design. Subjects cycled at approximately 70% of their VO2peak, coupled with five 2-min bursts at 85% VO2peak to simulate hill climbs over 2 h. Subjects then completed a time trial, which required them to complete 7 kJ/kg body mass as quickly as possible. Infrared spectrometry analysis showed a complete absence of Si-H bonds in MH. There was no difference in time trial performance between the 2 trials (PL: 2257+/-120 s vs. MH: 2345+/-152 s). Measured oxygen uptake, respiratory exchange ratio, carbohydrate (MH: 2.99+/-0.13 g/min; PL: 2.83+/-0.17 g/min avg. over 2 h) and fat (MH: 0.341+/-0.06 g/min; PL: 0.361+/-0.07 g/min) oxidation rates and all blood parameters (lactate, glucose, and free fatty acids) were all unaffected by MH supplementation. The volume of expired CO2 and ventilation were significantly greater with MH supplementation (P < or = 0.05). The results indicate that oral Microhydrin supplementation does not enhance cycling time trial performance or alter metabolism during prolonged submaximal exercise in endurance-trained cyclists. PMID: 15673102 [PubMed - indexed for MEDLINE] |
#548
|
|||
|
|||
 ãàçåòå ÀèÔ îïóáëèêîâàíà, ìÿãêî ãîâîðÿ, ïîäîçðèòåëüíàÿ èíôîðìàöèÿ, ïðèïèñûâàåìàÿ "Îáùåñòâó ñïåöèàëèñòîâ äîêàçàòåëüíîé ìåäèöèíû".
[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] Öèòàòà:
|
#549
|
|||
|
|||
Âñ¸ ðàçóìíî íàïèñàíî. Ýòî ôðàãìåíò èíòåðâüþ ñ Êèðèëëîì Äàíèøåâñêèì. ×òî Âàñ ñìóùàåò? Òî ÷òî ÝÊà áåññìûñëåííî äåëàòü âñåì ïîäðÿä - äàâíî èçâåñòíî. À àíàëèç êðîâè íå çàìåíÿåò îáùåíèå ñ ðàçóìíûì âðà÷îì/ìåäñåñòðîé ïî îïðåäåëåííîé ñõåìå.
Ïî÷åìó ýòà ðåïëèêà â òåìå ïðî øàðëàòàíñòâî? |
#550
|
|||
|
|||
Èìåííî ïîòîìó, ÷òî ÿ ñàì íå óâåðåí, ÿ è ïîïðîñèë ïðîêîììåíòèðîâàòü. Åñëè ÷åñòíî, ïîñëå ïðî÷òåíèÿ ñòàòüè âîçíèêëî îùóùåíèå, ÷òî æóðíàëèñòû ãîâîðèëè ñî ñïåöèàëèñòàìè, íî ÷òî-òî íàïóòàëè. Îñîáåííî óäèâèëà ôðàçà ïðî òî, ÷òî îáùèé àíàëèç êðîâè íå ýôôåêòèâåí â âûÿâëåíèè àíåìèè, è îáùàÿ èäåÿ ñòàòüè î òîì, ÷òî îáñëåäîâàòü íàäî òîëüêî òåõ, êòî ïðè îïðîñå ïðåäúÿâèë æàëîáû.
Íàñ÷¸ò ÝÊÃ. Ïðè àíàëèçå ÝÊà æåëàòåëüíî èìåòü âîçìîæíîñòü ñðàâíèâàòü å¸ ñ ÝÊà ïðîøëûõ ëåò. È êàê, äîïóñòèì, âûÿâèòü áåç ïëàíîâîé ÝÊà ÀÂ-áëîêàäó I ñòåïåíè, êîãäà åù¸ íåò íèêàêèõ æàëîá? Íå òàêîå óæ ýòî è äîðîãîñòîÿùåå èññëåäîâàíèå, çà÷åì îò íåãî îòêàçûâàòüñÿ? Ñ äðóãîé ñòîðîíû, ñî ìíîãèìè ìîìåíòàìè íå ìîãó íå ñîãëàñèòüñÿ: òåñòû íà ñêðûòóþ êðîâü â êàëå, ìàçêè íà ðàê øåéêè ìàòêè áûëè áû äåéñòâèòåëüíî ïîëåçíû. Òîëüêî ïî÷åìó íóæíî îòêàçûâàòüñÿ îò ïëàíîâûõ ÎÀÊ, ÎÀÌ è ÝÊÃ? Ðàäè ýêîíîìèè?  òàêîì ñëó÷àå, ñëåäóåò ïðåêðàòèòü íàçíà÷àòü ÎÀÊ è ÎÀÌ ïîñëå êàæäîãî ÎÐÇ, íî íå æåðòâîâàòü èìè âî âðåìÿ äèñïàíñåðèçàöèè. |
#551
|
|||||
|
|||||
Öèòàòà:
Öèòàòà:
Öèòàòà:
Öèòàòà:
Öèòàòà:
|
#552
|
|||
|
|||
ß ïðàâèëüíî ïîíÿëà, ÷òî íà ôëþîðîãðàôèþ ìîæíî îáîñíîâàííî íèêîãäà â æèçíè áîëüøå íå õîäèòü? Åñëè íåò òóáåðêóëåçíûõ æàëîá?
À äèñïàíñåðèçàöèÿ áåðåìåííûõ? Îíà èìååò ñìûñë? Èëè òîæå ìîæíî íå íîñèòü êàæäóþ íåäåëþ çàâåòíóþ áàíî÷êó? |
#553
|
||||
|
||||
Ñóøåñòâóþò åâðîïåéñêèå è àìåðèêàíñêèå ðåêîìåíäàöèè ïî âåäåíèþ áåðåìåííîñòè, îñíîâàííûå íà evidence. Ê ñîæàëåíèþ â Ðîññèè äåéñòâóåò ïðèêàç íîìåð 50, èäèîòñêèé è áåññìûñëåííûé.
|
#554
|
||||
|
||||
Öèòàòà:
Checkup Guidelines for Adults: Age 21-30 years: Annual history and physical, breast exam and pap smear, pelvic examination on females, weight and blood pressure. Cholesterol every fifth year, VDRL every five years, tuberculin skin test every 5-10 years, rectal exam and stool for occult blood times one during this period, annual Hct. and and UA, and glaucoma screen. Counseling in regard to health maintenance, instruction regarding self breast examination, and prescription for wellness management. Age 30-40 years: Annual screening history and physical examination, breast, pelvic and pap exam, rectal examination with stool for occult blood, possibly establish baseline profile with EKG and chest x-ray. Cholesterol every fifth year. Tuberculin skin test every 10 years. Consider urinalysis and Hct. annually. Should also consider a baseline mammogram at age 35. Age 40-above: Annual physical examination, breast mammogram's every 1-2 years until age 50 then annually, pap smear, stool for occult blood annually, height and weight annually, cholesterol every fifth year, Hct. and UA annually (optional). Consider flexible sigmoidoscopy every 4-5 years after age 50. Td every 5-10 years. Other exams that one may desire on a periodic basis are T4, lipid profile, chest x-ray, EKG every 3-5 years, and periodic CBC's. One should consider a glaucoma screen every two years and annually at age 55. Males age 50 and above should consider a PSA. May consider VDRL every 5 years. |
#555
|
||||
|
||||
[quote=yananshs;501984]Â ÑØÀ àíàëèç êðîâè ïîêà íèêòî íå îòìåíÿë. Õîòÿ â îáøåì ñèëüíî íå íàñòàèâàþò:
À ýòî ÷òî çà ãàéä, êåì âûïóùåí? Íà USPSTF íà ïåðâûé âçãëÿä íå ïîõîæå, ìíå ýòîò äàæå áîëüøå íðàâèòñÿ. |